Xcout Intel
Entos Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Entos Pharmaceuticals among biotech, pharmaceuticals companies — ranked by similarity to what Entos Pharmaceuticals actually does, not by market-cap band.
Subscribe to see Entos Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Entos Pharmaceuticals
Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company headquartered in Edmonton, Canada, specializing in the development of innovative delivery systems for genetic therapies.
Entos Pharmaceuticals at a glance
Entos Pharmaceuticals is a biotech, pharmaceuticals company headquartered in Canada. It has raised at least $4.1M across the 2 funding rounds on record. Its most recent funding round, Grant, raised $4M in March 2025. Xcout tracks 9 named people at Entos Pharmaceuticals, including Arun Raturi (CHIEF SCIENTIFIC OFFICER).
Entos Pharmaceuticals leadership
- Arun RaturiCHIEF SCIENTIFIC OFFICER
- Kimberly HenshawCHIEF OF STAFF
- Arun RaturiFOUNDER, CHIEF EXECUTIVE OFFICER
- Duncan RoySCIENTIFIC FOUNDER
- Chandra McAllisterHEAD OF MANUFACTURING
- Jailal (Jai) AblackLEAD SCIENTIST - FORMULATIONS & PROCESS CONTROL
3 more named people on record for Entos Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Entos Pharmaceuticals funding rounds
At least $4.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $4M | 1 named | |
| SEC Form D filing | $100,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Entos Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Entos Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Pharmaceuticals
Damona Pharmaceuticals is a biotechnology research company developing microcircuit precision medicines aimed at restoring cognitive functions across various brain disorders. The company is located in Toronto, Ontario.
Pharmaceuticals
Sarepta Therapeutics, Inc. operates as a biopharmaceutical firm with products already available on the market. Its primary objective is the research and advancement of genetic treatment modalities, encompassing RNA-targeted therapeutics and gene therapies, specifically for the management of rare diseases. The company's commercial offerings include EXONDYS 51, an injectable medication prescribed for Duchenne muscular dystrophy (DMD) patients whose genetic mutation in the dystrophin gene is responsive to exon 51 skipping. Similarly, VYONDYS 53 is provided for individuals with DMD who can benefit from exon 53 skipping. Sarepta is also actively developing several investigational therapies: AMONDYS 45, a product candidate that utilizes phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to bypass exon 45 of the dystrophin gene. SRP-5051, a peptide-conjugated PMO engineered to bind to exon 51 of dystrophin pre-mRNA. SRP-9001, a gene therapy initiative focused on micro-dystrophin for DMD. SRP-9003, a gene therapy program targeting limb-girdle muscular dystrophies. The company has established collaborative relationships with various partners, including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and maintains its corporate headquarters in Cambridge, Massachusetts.
Biotechnology
OncoSenX, Inc. is a late-stage preclinical biotechnology company headquartered in Seattle, Washington. The firm specializes in developing targeted cancer therapeutics and novel drug delivery pipelines. Its oncology technology works in coordination with parent company Entos's research platforms to advance precision gene therapies.
Biotech
NanoVation Therapeutics is a platform developer headquartered in Vancouver, British Columbia, that partners with leading pharmaceutical and biotech companies to enable genetic medicines.
Biotech
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Biotechnology
Kelonia Therapeutics, Inc. is a clinical-stage biotech company headquartered in Boston, Massachusetts, focused on delivering genetic medicine for patients.
Biotech
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
Biotech
Genevant Sciences is a biotechnology company headquartered in Vancouver, British Columbia, that develops world-class delivery platforms including lipid nanoparticles.
Healthcare & Life Sciences
ViaNautis Bio Ltd. is a groundbreaking nanomedicine company headquartered in Cambridge, UK, at the forefront of genetic therapies. The company leverages its proprietary polyNaut platform to develop novel products for delivering genetic medicines.
Healthcare
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Biotechnology
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Biotechnology
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Entos Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Entos Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →